Biomarin Pharmaceuticals
(BMRN)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2019 | 03-2019 | 12-2018 | 09-2018 | 06-2018 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 307,577 | 364,369 | 493,982 | 882,184 | 427,411 |
| Marketable Securities | 423,526 | 530,485 | 590,326 | 561,192 | 935,662 |
| Receivables | 377,150 | 393,429 | 342,633 | 384,343 | 363,566 |
| Inventories | 578,736 | 534,696 | 530,871 | 508,482 | 473,356 |
| Other current assets | 119,779 | 93,876 | 98,403 | 71,652 | 80,072 |
| TOTAL | $1,806,768 | $1,916,855 | $2,056,215 | $2,407,853 | $2,280,067 |
| Non-Current Assets | |||||
| PPE Net | 962,970 | 951,890 | 948,682 | 924,033 | 900,480 |
| Investments And Advances | 374,965 | 320,000 | 235,864 | 204,883 | 279,988 |
| Intangibles | 673,671 | 683,020 | 688,847 | 691,726 | 699,334 |
| Other Non-Current Assets | 575,010 | 563,633 | 497,520 | 466,759 | 464,810 |
| TOTAL | $2,586,616 | $2,518,543 | $2,370,913 | $2,287,401 | $2,344,612 |
| Total Assets | $4,393,384 | $4,435,398 | $4,427,128 | $4,695,254 | $4,624,679 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | N/A | N/A | N/A | 374,230 | 369,752 |
| Accounts payable and accrued liabilities | 439,428 | 500,986 | 523,241 | 464,430 | 435,198 |
| TOTAL | $439,428 | $500,986 | $523,241 | $838,660 | $804,950 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 993,002 | 997,785 | 935,947 | 941,649 | 934,625 |
| TOTAL | $993,002 | $997,785 | $935,947 | $941,649 | $934,625 |
| Total Liabilities | $1,432,430 | $1,498,771 | $1,459,188 | $1,780,309 | $1,739,575 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 179,463 | 179,071 | 178,372 | 178,062 | 177,590 |
| Common Shares | 179 | 179 | 178 | 178 | 178 |
| Retained earnings | -1,790,769 | -1,753,334 | -1,694,134 | -1,690,475 | -1,677,855 |
| Other shareholders' equity | 7,228 | 6,882 | -8,030 | -15,575 | -14,519 |
| TOTAL | $2,960,954 | $2,936,627 | $2,967,940 | $2,914,945 | $2,885,104 |
| Total Liabilities And Equity | $4,393,384 | $4,435,398 | $4,427,128 | $4,695,254 | $4,624,679 |